| 211.17 -16.27 (-7.15%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 265.49 |
1-year : | 277.98 |
| Resists | First : | 227.3 |
Second : | 238 |
| Pivot price | 226.59 |
|||
| Supports | First : | 210 |
Second : | 174.72 |
| MAs | MA(5) : | 223.11 |
MA(20) : | 227.07 |
| MA(100) : | 219.57 |
MA(250) : | 237.44 |
|
| MACD | MACD : | -1.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 27.4 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 278.95 | Low : | 189.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BIIB ] has closed below the lower bollinger band by 21.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BIIB ] is to continue within current trading range. Bollinger Bands are 1.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 217.78 - 218.93 | 218.93 - 219.91 |
| Low: | 207.31 - 208.6 | 208.6 - 209.69 |
| Close: | 209.06 - 211.24 | 211.24 - 213.09 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
Fri, 26 Jul 2024
Biogen (NASDAQ:BIIB) Shares Gap Down to $227.44 - MarketBeat
Fri, 26 Jul 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union - Biogen | Investor Relations
Thu, 25 Jul 2024
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Thu, 25 Jul 2024
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Wed, 24 Jul 2024
Is Biogen (BIIB) an Underappreciated Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 146 (M) |
| Shares Float | 145 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 93 (%) |
| Shares Short | 2,740 (K) |
| Shares Short P.Month | 3,020 (K) |
| EPS | 7.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 104.48 |
| Profit Margin | 12 % |
| Operating Margin | 27.2 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 8 % |
| Qtrly Rev. Growth | -7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 66.34 |
| EBITDA (p.s.) | 17.3 |
| Qtrly Earnings Growth | 1.1 % |
| Operating Cash Flow | 1,650 (M) |
| Levered Free Cash Flow | 900 (M) |
| PE Ratio | 26.42 |
| PEG Ratio | 3.6 |
| Price to Book value | 2.02 |
| Price to Sales | 3.18 |
| Price to Cash Flow | 18.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|